E
Elizabeth K. Norton
Researcher at Rensselaer Polytechnic Institute
Publications - 15
Citations - 1648
Elizabeth K. Norton is an academic researcher from Rensselaer Polytechnic Institute. The author has contributed to research in topics: Virus & Recombinant virus. The author has an hindex of 12, co-authored 15 publications receiving 1625 citations.
Papers
More filters
Journal ArticleDOI
NYVAC: a highly attenuated strain of vaccinia virus
James Tartaglia,Marion E. Perkus,Jill Taylor,Elizabeth K. Norton,Jean-Christophe Audonnet,William I. Cox,Stephen W. Davis,Johanna Van Der Hoeven,Bernard Meignier,Michel Riviere,Bernard Languet,Enzo Paoletti +11 more
TL;DR: The NYVAC strain was demonstrated to be highly attenuated by the following criteria: greatly reduced virulence as demonstrated by the results of intracranial challenge of both 3-week-old or newborn mice; greatly reduced pathogenicity and failure to disseminate in immunodeficient (nude or cyclophosphamide treated) mice.
Patent
NYVAC vaccinia virus recombinants comprising heterologous inserts
Enzo Paoletti,Marion E. Perkus,Jill Taylor,James Tartaglia,Elizabeth K. Norton,Michel Riviere,Charles de Taisne,Keith J. Limbach,Gerard P. Johnson,Steven E. Pincus,William I. Cox,Jean-Christophe Audonnet,Russell Robert Gettig +12 more
TL;DR: In this article, a modified recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety is described, where the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor.
Journal ArticleDOI
Vaccinia virus host range genes.
Marion E. Perkus,Scott J. Goebel,Stephen W. Davis,Gerard P. Johnson,Keith J. Limbach,Elizabeth K. Norton,Enzo Paoletti +6 more
TL;DR: A gene encoding an 18-kDa polypeptide located in the vaccinia virus HindIII C fragment was shown to be functionally equivalent to previously described host range gene (ORF K1L) spanning the HindIII K/M fragment junction.
Journal ArticleDOI
Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins.
Jill Taylor,Randall Weinberg,James Tartaglia,Christopher D. Richardson,Christopher D. Richardson,Ghalib Alkhatib,Dalius J. Briedis,Max J. G. Appel,Elizabeth K. Norton,Enzo Paoletti +9 more
TL;DR: The development of canarypox virus (CPV) recombinants expressing the hemagglutinin (HA) and fusion (F) glycoproteins of measles virus (MV) is described and elicit a protective immune response against a lethal canine distemper virus (CDV) challenge.
Patent
Genetically engineered vaccine strain
Enzo Paoletti,Marion E. Perkus,Jill Taylor,James Tartaglia,Elizabeth K. Norton,Michel Riviere,Taisne Charles De,Keith J. Limbach,Gerard P. Johnson,Steven E. Pincus,William I. Cox,Jean-Christophe Francis,Russell Robert Gettig +12 more
TL;DR: In this paper, a modified recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety is described, where the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor.